Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES MONTANO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1487673208
CMS profile
294754
Location
CROMWELL, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$50,419.65

211 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 5 of 5; records 201–211 of 211 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES MONTANO

NPI 1487673208 · CMS profile ID 294754

Allopathic & Osteopathic Physicians / Internal Medicine

CROMWELL, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–211 of 211 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487673208?year=2020&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES MONTANO, NPI 1487673208, CMS profile ID 294754. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–211 of 211 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487673208?year=2020&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CHARLES MONTANO, NPI 1487673208, CMS profile ID 294754. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–211 of 211 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487673208?year=2020&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CHARLES MONTANO, NPI 1487673208, CMS profile ID 294754, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–211 of 211 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1487673208?year=2020&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

211 matching records · $50,419.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 211 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–211 of 211.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $14.9001/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747269015 CMS
Allergan, Inc. $19.2201/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723271951 CMS
Neos Therapeutics, LP $15.4001/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753023241 CMS
Amarin Pharma Inc. $11.4201/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739832177 CMS
Supernus Pharmaceuticals, Inc. $26.3301/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748350923 CMS
AstraZeneca Pharmaceuticals LP $12.4701/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736058559 CMS
Adlon Therapeutics L.P. $22.0101/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749348763 CMS
Allergan, Inc. $3.8901/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723271943 CMS
Allergan, Inc. $13.2801/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723271945 CMS
Allergan, Inc. $31.5101/06/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723271947 CMS
Allergan, Inc. $1,920.0001/06/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723271949 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $114,875.87 340
PY2020 $50,419.65 211
PY2021 $79,427.87 261
PY2022 $68,545.98 263
PY2023 $185,998.03 339
PY2024 $178,802.83 372
PY2025 $291,917.25 428

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,612.49 7
PY2025 Principal investigator $291,920.04 119
PY2024 Recipient $8,649.00 2
PY2024 Principal investigator $803,962.75 106
PY2023 Recipient $49,421.36 10
PY2023 Principal investigator $191,996.02 31
PY2022 Principal investigator $272,984.79 71
PY2021 Recipient $35,295.40 7
PY2021 Principal investigator $132,283.19 47
PY2020 Recipient $3,304.21 19
PY2020 Principal investigator $112,711.56 29
PY2019 Recipient $33,476.95 5
PY2019 Principal investigator $39,567.22 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

126 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,445.60 12/31/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies No dispute reported 06/30/2026 1202534053
Principal investigator 1 ABBVIE INC. $852.28 12/31/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202534055
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655308
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655310
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655312
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655314
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655316
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655318
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655320
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655322
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655324
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655326
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655328
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655330
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655332
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655334
Principal investigator 1 PFIZER INC. $3,500.00 11/24/2025 Non-covered Recipient Entity
Elligo Health Research Inc
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228818509
Principal investigator 1 PFIZER INC. $2,900.00 11/24/2025 Non-covered Recipient Entity
Elligo Health Research Inc
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228818555
Principal investigator 1 PFIZER INC. $5,000.00 11/06/2025 Non-covered Recipient Entity
Elligo Health Research Inc
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228818549
Principal investigator 1 Boehringer Ingelheim International GmbH $6,801.35 10/22/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655258
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655286
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655288
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655290
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655292
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655294
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655296
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655298
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655300
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655302
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655304
Principal investigator 1 Boehringer Ingelheim International GmbH $4,999.00 10/02/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655306
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 09/03/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655256
Principal investigator 1 ABBVIE INC. $3,712.50 08/06/2025 Non-covered Recipient Entity
MONTANO WELLNESS LLC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202502873
Principal investigator 1 Boehringer Ingelheim International GmbH $2,200.00 07/28/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655270
Principal investigator 1 Boehringer Ingelheim International GmbH $2,200.00 07/28/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655272
Principal investigator 1 Boehringer Ingelheim International GmbH $2,200.00 07/28/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655274
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 07/28/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655278
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 07/28/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655280
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 07/25/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655254
Principal investigator 1 Boehringer Ingelheim International GmbH $9,500.00 07/23/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655268
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 07/23/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655276
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 07/23/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655282
Principal investigator 1 Boehringer Ingelheim International GmbH $65.00 07/23/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655284
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 07/11/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655252
Principal investigator 1 Boehringer Ingelheim International GmbH $2,200.00 06/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655260
Principal investigator 1 Boehringer Ingelheim International GmbH $2,200.00 06/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655262
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655264
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655266
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 05/23/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655236
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 05/23/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655238
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 05/23/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655240
Principal investigator 1 Boehringer Ingelheim International GmbH $650.00 05/23/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655244
Principal investigator 1 Boehringer Ingelheim International GmbH $2,100.00 05/23/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655246
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 05/14/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655230
Principal investigator 1 Boehringer Ingelheim International GmbH $1,037.00 05/14/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655232
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 05/14/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655234
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 05/14/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655242
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 05/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655248
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 05/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655250
Recipient ABBVIE INC. $998.58 04/10/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202399986
Recipient ABBVIE INC. $49.99 04/10/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202399990
Recipient ABBVIE INC. $24.99 04/10/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202399994
Recipient ABBVIE INC. $59.98 04/10/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202399998
Recipient ABBVIE INC. $24.99 04/10/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202400002
Recipient ABBVIE INC. $149.99 04/09/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202399979
Recipient ABBVIE INC. $303.97 04/09/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202399983
Principal investigator 1 Boehringer Ingelheim International GmbH $24,888.00 04/04/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655226
Principal investigator 1 Boehringer Ingelheim International GmbH $504.00 04/02/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655218
Principal investigator 1 Boehringer Ingelheim International GmbH $198.00 04/02/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655220
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 04/02/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655222
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 04/02/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655224
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 04/02/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655228
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 04/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655210
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 04/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655212
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 04/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655214
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 04/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655216
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 03/31/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655200
Principal investigator 1 Boehringer Ingelheim International GmbH $99.00 03/14/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655208
Principal investigator 1 Boehringer Ingelheim International GmbH $4,351.00 03/07/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655202
Principal investigator 1 Boehringer Ingelheim International GmbH $4,351.00 03/07/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655204
Principal investigator 1 Boehringer Ingelheim International GmbH $3,459.00 03/07/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655206
Principal investigator 1 PFIZER INC. $750.00 03/06/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228821877
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 03/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655188
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 03/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655190
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 03/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655192
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 03/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655194
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 02/28/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655198
Principal investigator 1 Boehringer Ingelheim International GmbH $198.00 02/24/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655178
Principal investigator 1 Boehringer Ingelheim International GmbH $3,778.00 02/19/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655166
Principal investigator 1 Boehringer Ingelheim International GmbH $3,778.00 02/19/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655168
Principal investigator 1 Boehringer Ingelheim International GmbH $3,778.00 02/19/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655170
Principal investigator 1 Boehringer Ingelheim International GmbH $3,940.00 02/19/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655172
Principal investigator 1 Boehringer Ingelheim International GmbH $4,890.00 02/19/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655174
Principal investigator 1 Boehringer Ingelheim International GmbH $4,890.00 02/19/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655176
Principal investigator 1 Boehringer Ingelheim International GmbH $264.55 02/10/2025 Non-covered Recipient Entity
CT Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220655336
Principal investigator 1 Boehringer Ingelheim International GmbH $495.00 02/03/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655162
Principal investigator 1 Boehringer Ingelheim International GmbH $478.00 02/03/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655164
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 02/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655180
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 02/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655182
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 02/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655184
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 02/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655186
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 01/31/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655196
Principal investigator 1 Eli Lilly and Company $260.00 01/31/2025 Non-covered Recipient Entity
CONNECTICUT CLINICAL RESEARCH INSTITUTE LLC
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187879663
Principal investigator 1 Eli Lilly and Company $941.58 01/31/2025 Non-covered Recipient Entity
CONNECTICUT CLINICAL RESEARCH INSTITUTE LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187880139
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,850.00 01/29/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC DBA PREFERRED RESEARCH PARTNERS INC
AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1242329851
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,625.00 01/29/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC DBA PREFERRED RESEARCH PARTNERS INC
AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1242329853
Principal investigator 1 PFIZER INC. $6,312.18 01/16/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228821883
Principal investigator 1 Boehringer Ingelheim International GmbH $3,108.00 01/15/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655130
Principal investigator 1 Boehringer Ingelheim International GmbH $5,037.00 01/15/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655132
Principal investigator 1 Boehringer Ingelheim International GmbH $3,108.00 01/15/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655134
Principal investigator 1 Boehringer Ingelheim International GmbH $5,037.00 01/15/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655136
Principal investigator 1 Boehringer Ingelheim International GmbH $4,351.00 01/15/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655138
Principal investigator 1 Boehringer Ingelheim International GmbH $3,459.00 01/15/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655140
Principal investigator 1 Boehringer Ingelheim International GmbH $4,351.00 01/15/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655142
Principal investigator 1 Boehringer Ingelheim International GmbH $3,459.00 01/15/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655144
Principal investigator 1 Boehringer Ingelheim International GmbH $5,029.00 01/15/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655146
Principal investigator 1 Boehringer Ingelheim International GmbH $3,940.00 01/15/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655148
Principal investigator 1 Boehringer Ingelheim International GmbH $5,029.00 01/15/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655150
Principal investigator 1 Boehringer Ingelheim International GmbH $378.00 01/15/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655152
Principal investigator 1 ABBVIE INC. $850.00 01/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting No dispute reported 06/30/2026 1202436885
Principal investigator 1 Eli Lilly and Company $51,292.00 01/06/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187879909
Principal investigator 1 Eli Lilly and Company $22,167.00 01/06/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187879913
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 01/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655154
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 01/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655156
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 01/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655158
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 01/01/2025 Non-covered Recipient Entity
CT Clinical Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220655160